MediciNova Presents Study Update And Interim Analysis Of Phase 2/3 Clinical Trial Of MN-166 In ALS At The 35th International Symposium On ALS/MND

BenzingaDec 5 18:04 ET

Express News | MediciNova Inc - Expects to Complete Patient Assignments by June 2025 With Trial Results Expected in 2026

ReutersDec 5 18:01 ET

Express News | MediciNova Inc - Positive Correlations Observed Between 6-Month and 12-Month Data

ReutersDec 5 18:00 ET

Express News | Medicinova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) at the 35TH International Symposium on ALS/Mnd

ReutersDec 5 18:00 ET

This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

BenzingaDec 2 08:56 ET

D. Boral Capital Initiates MediciNova(MNOV.US) With Buy Rating, Announces Target Price $9

Moomoo NewsDec 2 08:32 ET · Ratings